COMMUNIQUÉS West-GlobeNewswire

23andMe Research Institute to Showcase Scientific Impact and Expanded Research Capabilities at ASHG 2026
19/10/2026
New research and capabilities highlight the power of more than 11 million consented research participants PALO ALTO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- At the American Society of Human Genetics (ASHG) 2026 Annual [...]
XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
19/10/2026
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals [...]
TerrAscend to Host Third Quarter 2026 Earnings Conference Call
19/10/2026
TORONTO, Oct. 19, 2026 (GLOBE NEWSWIRE) -- TerrAscend Corp. (the "Company") (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today announced that it will host a scheduled conference call to [...]
Final Safety, Pharmacokinetic and Pharmacodynamic Data from COL-5671 Phase 1 Clinical Study Presented at UEGW
19/10/2026
COL-5671, a highly selective oral SIK3 inhibitor, demonstrated a favorable safety and pharmacokinetic (PK) profile Pharmacodynamic (PD) data indicate potent TNFα suppression at low doses , with even greater IL-23 [...]
VIVUS Announces Positive Outcome of European Procedure to Extend QSIVA® (Phentermine/Topiramate MR) to Adolescents with Obesity
19/10/2026
— Landmark European approval will grant young patients and families an evidence-based therapy alongside lifestyle interventions AMSTERDAM, Oct. 19, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a [...]
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
19/10/2026
ALISO VIEJO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced the appointments of Taryn Conway as Chief Commercial Officer and Frank Shields as Executive Vice President of Sales and [...]
ProSomnus Announces Significant Scientific, Technical, and Advocacy Updates
19/10/2026
World-Renowned Sleep Medicine Leaders Join ProSomnus Medical Advisory Board, RPMO₂ Enhancements, Published FLOSAT Study Results, and Scientific Contributions at CHEST 2026 SAN FRANCISCO, Oct. 19, 2026 (GLOBE NEWSWIRE [...]
Beacon Biosignals Partners with Project Sleep to Shorten the Path to Diagnosis for People with Idiopathic Hypersomnia and Narcolepsy
19/10/2026
The partnership connects Beacon's AI-driven neurotechnology with the patient-led advocacy community, expanding access to diagnosis and bringing patient voices directly into clinical research BOSTON, Oct. 19, 2026 (GLOBE [...]
Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer
19/10/2026
Premier sponsorship of the HERmedicine and OncoMenopause Consortium ® program underscores Daré Bioscience's commitment to addressing unmet women’s health needs, including for women affected by breast cancer The program [...]
OneMedNet Signs Global Pharmaceutical Intelligence Provider as Channel Partner, Extending Reach in Pharma Market
19/10/2026
Agreement with a leading global provider of pharmaceutical intelligence and data solutions expands distribution of OneMedNet’s first-party, direct-from-source multimodal Real-World Data; Strengthening its presence in a [...]
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
19/10/2026
TEL AVIV, Israel, Oct. 19, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), announced that it will shift its strategic focus toward Agentic AI-powered technologies, including [...]
Fangzhou and Cutia Therapeutics Partner to Advance AI-Powered Dermatology and Chronic Health Management
19/10/2026
GUANGZHOU, China, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI‑driven Internet healthcare solutions, announced a strategic partnership with Cutia [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
19/10/2026
In advance of November 10, 2026 GDUFA goal date, three commercial lots of Preservative-Free Ketamine have been successfully manufactured in compliance with “Process Validation” required under FDA “Good Manufacturing [...]
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
19/10/2026
ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system [...]
Indivior to Report Third Quarter 2026 Financial Results
19/10/2026
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29, 2026. The results will [...]
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
19/10/2026
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
J-Star Holding Co., Ltd. Advances U.S. Drone Manufacturing Initiative; Negotiates Acquisition of Facility in the Greater Houston Area
19/10/2026
Company is Organizing an Independent Texas-based Manufacturing Platform, Contributing Proprietary Composite Technology and Engineering Expertise to Support Planned U.S. Drone-Frame Production Strategic Real Estate [...]
Alpha Tau Announces FDA Approval to Expand Alpha DaRT® U.S. Recurrent Glioblastoma REGAIN Trial; New Trial Data to be Presented at SNO 2026 Annual Meeting
19/10/2026
- FDA approves IDE supplement expanding REGAIN from 10 to 20 patients, with additional study endpoints and interim analysis - - Abstract authored by REGAIN study principal investigator Dr. Joshua Palmer of The Ohio [...]
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
19/10/2026
- Largest Shareholder Increases Position as Dogwood Advances Halneuron ® Toward Topline Phase 2b Data Readout in November 2026 - - Expected Proceeds from the Investment Enable Acceleration of Phase 3 Preparatory [...]

Pages